Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial

Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial

Abstract Background To evaluate the efficacy and safety of nimotuzumab combined with docetaxel and cisplatin (TPN) as the first-line therapy in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Methods In this multicenter, open-label, phase 2 trial (ClinicalTrials.gov identifi...

Full description

Saved in:
Bibliographic Details
Main Authors: Qihua Zou, Yi Cao, Yulin Lai, Yu Fang, Yuchen Zhang, Panpan Liu, Lixia Lu, Hao Wu, Tianying Huang, Ning Su, Zhihua Li, Xicheng Wang, Xiaopeng Tian, Lirong Li, Yingxian Liu, Qingqing Cai, Yi Xia
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Medicine
Subjects:
Nimotuzumab
Docetaxel
Cisplatin
First-line therapy
Recurrent or metastatic nasopharyngeal carcinoma
Online Access:https://doi.org/10.1186/s12916-025-04103-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12916-025-04103-0

Similar Items